This androgen-driven mechanism leads to elevated estrogen levels, offering new insights into the complex pathophysiology of PCOS and strengthening the rationale for targeting the AR-FOXL2-aromatase axis as a therapeutic strategy for ovulation induction in PCOS patients. The gene discussed is CYP19A1; the disease is polycystic ovary syndrome.